688276 百克生物
已收盘 10-12 15:00:00
资讯
新帖
简况
股市必读：百克生物（688276）10月9日董秘有最新回复
证券之星 · 10-12 05:02
股市必读：百克生物（688276）10月9日董秘有最新回复
股市必读：长春百克生物科技（688276）9月24日董秘有最新回复
证券之星 · 09-28
股市必读：长春百克生物科技（688276）9月24日董秘有最新回复
百克生物：液体鼻喷流感疫苗正在开展适用于18-59岁人群的III期临床试验
证券之星 · 09-24
百克生物：液体鼻喷流感疫苗正在开展适用于18-59岁人群的III期临床试验
股市必读：长春百克生物科技新发布《长春百克生物科技股份公司关于自愿披露重组人源抗呼吸道合胞病毒单克隆抗体注射液组合制剂临床试验申请获得受理的公告》
证券之星 · 09-23
股市必读：长春百克生物科技新发布《长春百克生物科技股份公司关于自愿披露重组人源抗呼吸道合胞病毒单克隆抗体注射液组合制剂临床试验申请获得受理的公告》
百克生物最新公告：RSV抗体临床试验申请获受理
证券之星 · 09-22
百克生物最新公告：RSV抗体临床试验申请获受理
9月21日长春百克生物科技涨5.65%，金鹰鑫瑞混合A基金重仓该股
证券之星 · 09-21
9月21日长春百克生物科技涨5.65%，金鹰鑫瑞混合A基金重仓该股
百克生物：2026年上半年疫苗产品出口实现收入2,759.06万元
证券之星 · 09-18
百克生物：2026年上半年疫苗产品出口实现收入2,759.06万元
百克生物：液体鼻喷流感疫苗正在开展III期临床试验
证券之星 · 09-18
百克生物：液体鼻喷流感疫苗正在开展III期临床试验
9月18日长春百克生物科技涨10.09%，金鹰鑫瑞混合A基金重仓该股
证券之星 · 09-18
9月18日长春百克生物科技涨10.09%，金鹰鑫瑞混合A基金重仓该股
百克生物2026年半年报：营收增6.89%，研发投入节奏趋稳
蓝鲸财经 · 08-21
百克生物2026年半年报：营收增6.89%，研发投入节奏趋稳
图解百克生物中报：第二季度单季净利润同比增长34.85%
证券之星 · 08-21
图解百克生物中报：第二季度单季净利润同比增长34.85%
股市必读：百克生物（688276）登8月20日交易所龙虎榜
证券之星 · 08-21
股市必读：百克生物（688276）登8月20日交易所龙虎榜
8月20日百克生物创60日新高，金鹰鑫瑞混合A基金重仓该股
证券之星 · 08-20
8月20日百克生物创60日新高，金鹰鑫瑞混合A基金重仓该股
生物疫苗股全线大涨，康希诺等5股20CM涨停，默沙东莫德纳黑色素瘤疫苗临床试验传捷报
格隆汇 · 08-20
生物疫苗股全线大涨，康希诺等5股20CM涨停，默沙东莫德纳黑色素瘤疫苗临床试验传捷报
每周股票复盘：百克生物（688276）将召开2026年半年度业绩说明会
证券之星 · 08-16
每周股票复盘：百克生物（688276）将召开2026年半年度业绩说明会
股市必读：百克生物新发布《长春百克生物科技股份公司关于召开2026年半年度业绩说明会的公告》
证券之星 · 08-14
股市必读：百克生物新发布《长春百克生物科技股份公司关于召开2026年半年度业绩说明会的公告》
百克生物（688276）披露2026年半年度业绩说明会公告，8月12日股价下跌1.01%
证券之星 · 08-12
百克生物（688276）披露2026年半年度业绩说明会公告，8月12日股价下跌1.01%
股市必读：百克生物（688276）7月24日披露最新机构调研信息
证券之星 · 07-27
股市必读：百克生物（688276）7月24日披露最新机构调研信息
每周股票复盘：百克生物（688276）液体剂型获批将供货
证券之星 · 07-26
每周股票复盘：百克生物（688276）液体剂型获批将供货
百克生物：7月24日组织现场参观活动，东海证券、北京峰谷资本管理有限公司等多家机构参与
证券之星 · 07-24
百克生物：7月24日组织现场参观活动，东海证券、北京峰谷资本管理有限公司等多家机构参与
加载更多
公司概况
公司名称：
长春百克生物科技股份公司
所属行业：
医药制造业
上市日期：
2021-06-25
主营业务：
长春百克生物科技股份公司的主营业务是传染病防治的创新生物药的研发、生产及销售。公司的主要产品是水痘疫苗、鼻喷流感疫苗、带状疱疹疫苗、液体鼻喷流感疫苗。
发行价格：
36.35
{"stockData":{"symbol":"688276","market":"SH","secType":"STK","nameCN":"百克生物","latestPrice":17.45,"timestamp":1791788400000,"preClose":17.79,"halted":0,"volume":2925527,"delay":0,"changeRate":-0.0191,"floatShares":413999999,"shares":413999999,"eps":-0.5829,"marketStatus":"已收盘","change":-0.34,"latestTime":"10-12 15:00:00","open":17.86,"high":18.13,"low":17.27,"amount":51288800,"amplitude":0.0483,"askPrice":17.46,"askSize":30,"bidPrice":17.45,"bidSize":12,"shortable":0,"etf":0,"ttmEps":-0.5829,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791855000000},"marketStatusCode":5,"adr":0,"adjPreClose":17.79,"symbolType":"stock_kcb","openAndCloseTimeList":[[1791768600000,1791775800000],[1791781200000,1791788400000]],"highLimit":19.57,"lowLimit":16.01,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":413657598,"isCdr":false,"pbRate":1.9,"roa":"--","roe":"--","epsLYR":-0.64,"committee":0.313043,"marketValue":7218000000,"turnoverRate":0.0071,"status":1,"afterMarket":{"amount":0,"volume":0,"close":17.45,"buyVolume":0,"sellVolume":0,"time":1791790437746,"indexStatus":"已收盘 10-12 15:30:00","preClose":17.79},"floatMarketCap":7218000000},"requestUrl":"/m/hq/s/688276","defaultTab":"news","newsList":[{"id":"2674496628","title":"股市必读：百克生物（688276）10月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2674496628","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674496628?lang=zh_cn&edition=full","pubTime":"2026-10-12 05:02","pubTimestamp":1791752538,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，百克生物报收于17.79元，上涨2.65%，换手率0.95%，成交量3.93万手，成交额6806.12万元。其中，HSV-2 mRNA疫苗是公司mRNA技术平台的重磅产品，当前全球暂无相关疫苗产品成功开发上市。此外，公司投资的传信生物致力于mRNA技术的开发及应用，传信生物研发的通用型肿瘤mRNA疫苗正在开展IIT临床试验，截至2026年6月，已完成13例患者入组和全部计划给药，未出现DLT事件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200001630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670749409","title":"股市必读：长春百克生物科技（688276）9月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2670749409","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670749409?lang=zh_cn&edition=full","pubTime":"2026-09-28 02:28","pubTimestamp":1790533694,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，长春百克生物科技报收于17.75元，下跌2.69%，换手率1.02%，成交量4.22万手，成交额7584.81万元。研发管线方面，截至目前，公司处于临床试验阶段或已获批临床试验的项目共12项。当日关注点交易信息汇总：9月24日主力资金净流出453.83万元，占总成交额5.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669246574","title":"百克生物：液体鼻喷流感疫苗正在开展适用于18-59岁人群的III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2669246574","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669246574?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:09","pubTimestamp":1790240957,"startTime":"0","endTime":"0","summary":"证券之星消息，长春百克生物科技09月24日在投资者关系平台上答复投资者关心的问题。研发管线方面，截至目前，公司处于临床试验阶段或已获批临床试验的项目共12项。公司将同步推进阿尔茨海默病治疗性疫苗等多个研发项目的临床前研究工作，不断完善公司产品结构，持续增强核心竞争力。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400029391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669812955","title":"股市必读：长春百克生物科技新发布《长春百克生物科技股份公司关于自愿披露重组人源抗呼吸道合胞病毒单克隆抗体注射液组合制剂临床试验申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669812955","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669812955?lang=zh_cn&edition=full","pubTime":"2026-09-23 01:34","pubTimestamp":1790098450,"startTime":"0","endTime":"0","summary":"公司公告汇总长春百克生物科技股份公司关于自愿披露重组人源抗呼吸道合胞病毒单克隆抗体注射液组合制剂临床试验申请获得受理的公告长春百克生物科技股份公司近日收到国家药品监督管理局下发的重组人源抗呼吸道合胞病毒单克隆抗体注射液组合制剂临床试验申请的《受理通知书》，受理号为CXSL2601038。目前国内市场已获批4款RSV抗体，公司此次申报的产品为鸡尾酒组合制剂，中和活性更强。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300002237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669014619","title":"百克生物最新公告：RSV抗体临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2669014619","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669014619?lang=zh_cn&edition=full","pubTime":"2026-09-22 19:01","pubTimestamp":1790074860,"startTime":"0","endTime":"0","summary":"百克生物(688276.SH)公告称，公司近日收到国家药监局下发的重组人源抗呼吸道合胞病毒单克隆抗体注射液组合制剂临床试验申请的《受理通知书》。该产品用于预防新生儿和婴幼儿RSV引起的下呼吸道感染，为鸡尾酒组合制剂，相比国内已获批的4款单价产品具有更强中和活性。该项目临床试验申请获受理，有助于优化产品结构，增强长期盈利能力，但对近期业绩不会产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200035149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669715915","title":"9月21日长春百克生物科技涨5.65%，金鹰鑫瑞混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669715915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669715915?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:41","pubTimestamp":1789980113,"startTime":"0","endTime":"0","summary":"证券之星消息，9月21日长春百克生物科技涨5.65%，收盘报17.75元，换手率1.8%，成交量7.43万手，成交额1.29亿元。重仓长春百克生物科技的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为金鹰基金的金鹰鑫瑞混合A。金鹰鑫瑞混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668194184","title":"百克生物：2026年上半年疫苗产品出口实现收入2,759.06万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668194184","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668194184?lang=zh_cn&edition=full","pubTime":"2026-09-18 16:51","pubTimestamp":1789721486,"startTime":"0","endTime":"0","summary":"证券之星消息，长春百克生物科技(688276)09月18日在投资者关系平台上答复投资者关心的问题。投资者提问：公司海外项目进展如何长春百克生物科技回复：尊敬的投资者您好，公司持续围绕“深化既有市场，突破重点项目，拓展经销商网络，提升国际化影响力”的核心策略，重点维护与深耕现有国际市场，例如印度、印度尼西亚、巴基斯坦等水痘疫苗市场；通过与现有国际经销商建立更紧密的战略协同，制定并优化营销策略，以提升市场份额。2026年上半年，疫苗产品出口实现收入2,759.06万元，同比增长184.27%。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800026045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668418169","title":"百克生物：液体鼻喷流感疫苗正在开展III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2668418169","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668418169?lang=zh_cn&edition=full","pubTime":"2026-09-18 16:51","pubTimestamp":1789721485,"startTime":"0","endTime":"0","summary":"证券之星消息，长春百克生物科技09月18日在投资者关系平台上答复投资者关心的问题。投资者提问：公司各研发项目进展如何，是否有使用AI工具加速长春百克生物科技回复：尊敬的投资者您好，截至目前，公司处于临床试验阶段或已获批临床试验的项目共11项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800026043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668949417","title":"9月18日长春百克生物科技涨10.09%，金鹰鑫瑞混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2668949417","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668949417?lang=zh_cn&edition=full","pubTime":"2026-09-18 16:41","pubTimestamp":1789720894,"startTime":"0","endTime":"0","summary":"证券之星消息，9月18日长春百克生物科技涨10.09%，收盘报16.8元，换手率2.34%，成交量9.7万手，成交额1.6亿元。重仓长春百克生物科技的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为金鹰基金的金鹰鑫瑞混合A。金鹰鑫瑞混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800025813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661256086","title":"百克生物2026年半年报：营收增6.89%，研发投入节奏趋稳","url":"https://stock-news.laohu8.com/highlight/detail?id=2661256086","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661256086?lang=zh_cn&edition=full","pubTime":"2026-08-21 10:12","pubTimestamp":1787278349,"startTime":"0","endTime":"0","summary":"长春百克生物科技股份公司2026年上半年财报显示，公司实现营业收入3.05亿元，同比增长6.89%；归母净利润为-5,210.01万元，同比减亏2,147.33万元；扣非净利润为-5,351.59万元，同比减亏2,871.65万元。营收结构持续聚焦核心产品，现金流改善显著水痘疫苗与带状疱疹疫苗构成公司收入核心，其中水痘疫苗仍为第一大单品，带状疱疹疫苗通过主动价格管理提升盈利贡献，二者共同驱动营收同比增长6.89%。增值税税率由3%调整为13%，对收入确认节奏及税负水平产生影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787276545823920958","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661239233","title":"图解百克生物中报：第二季度单季净利润同比增长34.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661239233","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661239233?lang=zh_cn&edition=full","pubTime":"2026-08-21 01:55","pubTimestamp":1787248517,"startTime":"0","endTime":"0","summary":"证券之星消息，百克生物2026年中报显示，上半年度公司主营收入3.05亿元，同比上升6.89%；归母净利润-5210.01万元，同比上升29.19%；扣非净利润-5351.59万元，同比上升34.92%；其中2026年第二季度，公司单季度主营收入1.57亿元，同比上升28.19%；单季度归母净利润-4862.6万元，同比上升34.85%；单季度扣非净利润-4850.85万元，同比上升38.46%；负债率26.05%，投资收益-2063.41万元，财务费用222.03万元，毛利率78.42%。财报数据概要请见下图:本文数据来源于百克生物2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100001366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661005236","title":"股市必读：百克生物（688276）登8月20日交易所龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2661005236","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661005236?lang=zh_cn&edition=full","pubTime":"2026-08-21 00:53","pubTimestamp":1787244787,"startTime":"0","endTime":"0","summary":"截至2026年8月20日收盘，百克生物报收于18.71元，上涨20.01%，涨停，换手率1.57%，成交量6.49万手，成交额1.21亿元。当日关注点交易信息汇总：8月20日主力资金净流入3818.3万元，占总成交额31.45%。交易信息汇总：百克生物因日收盘价格涨幅达15%登上沪深交易所龙虎榜，为近5个交易日内首次上榜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100000858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660402433","title":"8月20日百克生物创60日新高，金鹰鑫瑞混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660402433","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660402433?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:37","pubTimestamp":1787215049,"startTime":"0","endTime":"0","summary":"证券之星消息，8月20日百克生物涨20.01%创60日新高，收盘报18.71元，换手率1.57%，成交量6.49万手，成交额1.21亿元。重仓百克生物的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为金鹰基金的金鹰鑫瑞混合A。金鹰鑫瑞混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000028861.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660727484","title":"生物疫苗股全线大涨，康希诺等5股20CM涨停，默沙东莫德纳黑色素瘤疫苗临床试验传捷报","url":"https://stock-news.laohu8.com/highlight/detail?id=2660727484","media":"格隆汇","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660727484?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:47","pubTimestamp":1787190439,"startTime":"0","endTime":"0","summary":"8月20日，A股市场生物疫苗股全线大涨，其中，百克生物、康希诺、沃森生物、莱美药业、智飞生物20CM涨停，康华生物逼近20CM涨停，康泰生物涨超17%，华兰疫苗涨超10%，德展健康、双鹭药业、海普瑞、海欣股份、万泰生物10CM涨停，金迪克、博晖创新涨超7%，西藏药业、卫光生物、利德曼、冠昊生物、塞力医疗、赛升药业、申联生物、欧林生物涨超6%。消息面上，默沙东与莫德纳周三宣布，联合研发的黑色素瘤皮肤癌疫苗在首次晚期临床试验中取得积极初步结果。\n\n港股频道更多独家策划、专家专栏，免费查阅>>\n\n 责任编辑：栎树","market":"us","thumbnail":"http://imgcloud.jrjimg.cn/2026/08/cms_20260820094719181.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2026/08/cms_20260820094719181.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/08/20094758182842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1989772923.USD","LU2023250504.SGD","FHLC","LU1201861249.SGD","LU1989772840.SGD","LU0985320562.USD","IE00BJJMRZ35.SGD","IE00B1BXHZ80.USD","LGHT","LU0320765489.SGD","LU0265550359.USD","LU1923622614.USD","300006","VHT","MRNX","LU0965509010.AUD","BK4568","LU0868494617.USD","XLV","301207","IHE","LU0130517989.USD","LU2089984988.USD","LU0289739699.SGD","LU2023250843.SGD","LU0124676726.USD","LU2580892789.USD","SG9999014559.SGD","LU2148510915.USD","IE00B2B36J28.USD","LU1162221912.USD","BK4516","IE00BLSP4452.SGD","LU1699723380.USD","MRNY","LU1116320737.USD","IE0002141913.USD","LU1941712264.USD","LU0098860793.USD","LU2433249047.HKD","PAWZ","BK4551","BK4501","LU0058720904.USD","IE00BN8TJ469.HKD","RXL","LU1934455277.USD","LU1061106388.HKD","LU0477156953.USD","LU2491050071.SGD","SG9999015358.SGD","LU0266013472.USD","LU1064130708.USD","LU1291159041.SGD","LU1929549753.HKD","LU1571399168.USD","LU1064131003.USD","06185","LU2324357040.USD","SG9999001176.SGD","SG9999014567.USD","IE00BFTCPJ56.SGD","LU1934455863.HKD","LU2357627491.SGD","BK0070","LU2125154778.USD","SG9999001440.SGD","LU1069347547.HKD","LU1066053197.SGD","BK0239","BK4585","LU1093756325.SGD","LU1983299246.USD","688185","LU2125909247.SGD","TRUH","300122","BK4533","LU0689626769.HKD","SG9999001176.USD","BK0077","LU2112291526.USD","BK4534","LU0265550946.USD","BK0196","WDNA","LU0980610538.SGD","300142","SG9999015341.SGD","BK4548","LU1974910355.USD","LU0006306889.USD","LU0122379950.USD","LU0238689110.USD","LU1917777945.USD","LU1989771016.USD","IE000M9KFDE8.USD","LU2491049909.HKD","SG9999014575.USD","LU0208291251.USD","LU0965508806.USD","LU1328615791.USD","LU1585245621.USD","LU0648001328.SGD","LU1057294990.SGD","LU0823416689.USD","IE00B4R5TH58.HKD","SGXZ57979304.SGD","IE0009355771.USD","LU2361045086.USD","LU1093756168.USD","IE00BBT3K403.USD","LU0861579265.USD","FTXH","LU2125909593.SGD","LU2461242641.AUD","LU2580892862.HKD","LU0106261372.USD","GDOC","LU0320765646.SGD","LU1037948541.HKD","IE00BSNM7G36.USD","BK4139","IYH","MRK","LU0070302665.USD","LU0234572021.USD","BK4588","LU0965509283.SGD","MRNA","BK0188","688276","BK4532","LU0942090050.USD","SG9999013999.USD","LU0211331839.USD","LU2361044949.HKD","IDNA","LU0859254822.USD","HRTS","LU2468319806.SGD","BK4007","IXJ","LU1023059063.AUD","BK4559","LU1035773651.USD","LU1066051811.HKD","LU0868494708.USD","LU2106854487.HKD","LU2360032135.SGD","LU0203347892.USD","JDOC","LU1430594728.SGD","LU0965509101.SGD","IE00BLSP4239.USD","SG9999002224.SGD","LU0203345920.USD","LU0432979614.USD","LU2491050154.USD","PPH","LU2361044865.SGD","SG9999002232.USD","LU0130102774.USD","LU1066051498.USD","SG9999014542.SGD","LU1116320901.HKD","GNOM","LU2125154935.USD","LU1066051225.USD","LU1941712348.USD","BK0046","BK4550","LU1934455194.USD","IE00BJT1NW94.SGD","LU1037948897.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659176681","title":"每周股票复盘：百克生物（688276）将召开2026年半年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2659176681","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659176681?lang=zh_cn&edition=full","pubTime":"2026-08-16 03:00","pubTimestamp":1786820441,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，百克生物报收于15.97元，较上周的15.61元上涨2.31%。本周，百克生物8月14日盘中最高价报16.29元。百克生物当前最新总市值66.06亿元，在生物制品板块市值排名37/51，在两市A股市值排名2564/5207。公司公告汇总长春百克生物科技股份公司将于2026年8月21日09:00-10:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会，介绍公司经营成果及财务状况。投资者可于2026年8月14日至8月20日16:00前通过上证路演中心网站或公司邮箱ir@bchtpharm.com提交问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659444161","title":"股市必读：百克生物新发布《长春百克生物科技股份公司关于召开2026年半年度业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659444161","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659444161?lang=zh_cn&edition=full","pubTime":"2026-08-14 02:21","pubTimestamp":1786645271,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，百克生物报收于15.96元，上涨1.33%，换手率0.7%，成交量2.88万手，成交额4596.35万元。公司公告汇总：百克生物将于2026年8月21日召开2026年半年度业绩说明会，副董事长孔维、董事总经理姜春来等高管将出席。公司公告汇总长春百克生物科技股份公司关于召开2026年半年度业绩说明会的公告长春百克生物科技股份公司将于2026年8月21日09:00-10:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会，介绍公司经营成果及财务状况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400001435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658973446","title":"百克生物（688276）披露2026年半年度业绩说明会公告，8月12日股价下跌1.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658973446","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658973446?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:33","pubTimestamp":1786527193,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，百克生物报收于15.75元，较前一交易日下跌1.01%，最新总市值为65.15亿元。该股当日开盘15.8元，最高16.06元，最低15.68元，成交额达2966.41万元，换手率为0.45%。公告显示，公司将于2026年8月21日09:00-10:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会，介绍公司经营成果及财务状况。投资者可于2026年8月14日至8月20日16:00前通过上证路演中心网站或公司邮箱ir@bchtpharm.com提交问题。说明会后可通过该平台查看会议内容。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200029949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654064673","title":"股市必读：百克生物（688276）7月24日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2654064673","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654064673?lang=zh_cn&edition=full","pubTime":"2026-07-27 02:05","pubTimestamp":1785089115,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，百克生物报收于13.92元，下跌3.06%，换手率0.41%，成交量1.71万手，成交额2401.39万元。当日关注点交易信息汇总：7月24日主力资金净流入235.31万元，散户资金净流出251.75万元。公司流感疫苗扩大适用人群的III期临床研究于2025年8月正式启动，目前全国各中心有序推进。如有相关计划，公司将根据监管要求及时进行披露，感谢您的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700001003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654574490","title":"每周股票复盘：百克生物（688276）液体剂型获批将供货","url":"https://stock-news.laohu8.com/highlight/detail?id=2654574490","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654574490?lang=zh_cn&edition=full","pubTime":"2026-07-26 02:49","pubTimestamp":1785005349,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，百克生物报收于13.92元，较上周的14.74元下跌5.56%。本周，百克生物7月20日盘中最高价报15.0元。百克生物当前最新总市值57.58亿元，在生物制品板块市值排名37/51，在两市A股市值排名2584/5200。参考目前国家对流感防控的要求和政策支持，公司将结合市场情况，适当安排生产，保障市场供应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653208634","title":"百克生物：7月24日组织现场参观活动，东海证券、北京峰谷资本管理有限公司等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2653208634","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653208634?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:31","pubTimestamp":1784889072,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年7月24日百克生物发布公告称公司于2026年7月24日组织现场参观活动，东海证券、北京峰谷资本管理有限公司、吉林烁德富家能源科技有限公司、吉林省安华通信集团有限公司、投资者、中国银行、中信银行、吉林省信托有限责任公司、吉林省亚东国有资本投资有限公司、吉林省投资基金有限公司、吉林省工业技术研究院集团有限公司、吉林省盛汇基金管理有限公司、长春汽车城国有资本投资运营有限公司参与。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400033933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239","161027"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791844476894,"stockEarnings":[{"period":"1week","weight":-0.0279},{"period":"1month","weight":0.1688},{"period":"3month","weight":0.1664},{"period":"6month","weight":-0.0327},{"period":"1year","weight":-0.2043},{"period":"ytd","weight":-0.0748}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":-0.0234},{"period":"3month","weight":-0.0428},{"period":"6month","weight":-0.0571},{"period":"1year","weight":-0.0256},{"period":"ytd","weight":-0.0432}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春百克生物科技股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11599人(较上一季度减少0.95%)","perCapita":"35663股","listingDate":"2021-06-25","address":"吉林省长春市朝阳区高新开发区火炬路1260号","registeredCapital":"41365万元","survey":" 长春百克生物科技股份公司的主营业务是传染病防治的创新生物药的研发、生产及销售。公司的主要产品是水痘疫苗、鼻喷流感疫苗、带状疱疹疫苗、液体鼻喷流感疫苗。","listedPrice":36.35},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百克生物(688276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百克生物(688276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百克生物,688276,百克生物股票,百克生物股票老虎,百克生物股票老虎国际,百克生物行情,百克生物股票行情,百克生物股价,百克生物股市,百克生物股票价格,百克生物股票交易,百克生物股票购买,百克生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百克生物(688276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百克生物(688276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}